Data as of 3:21pm ET
| -1.14 / -1.75%|
The 8 analysts offering 12-month price forecasts for Synageva Biopharma Corp have a median target of 68.00, with a high estimate of 72.00 and a low estimate of 52.00. The median estimate represents a +6.37% increase from the last price of 63.93.
The current consensus among 8 polled investment analysts is to Buy stock in Synageva Biopharma Corp. This rating has held steady since November, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.